Daniel A. Haber
Howard Hughes Medical Institute · 624 works · 109,874 citations · h-index 137
Top works
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development
- Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
- Isolation of rare circulating tumour cells in cancer patients by microchip technology
- Epidermal growth factor receptor mutations in lung cancer
- Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
- hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- Exon amplification: a strategy to isolate mammalian genes based on RNA splicing.
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
- Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
- Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
- Germ-LineBRCA1Mutations in Jewish and Non-Jewish Women with Early-Onset Breast Cancer
- An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor
- A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
- Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
- Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors